




RealRate

PHARMACEUTICAL 2018

ImmunoCellular Therapeutics Ltd.
Rank 330 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

ImmunoCellular Therapeutics Ltd. Rank 330 of 349

The relative strengths and weaknesses of ImmunoCellular Therapeutics Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoCellular Therapeutics Ltd. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 677% points. The greatest weakness of ImmunoCellular Therapeutics Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 832% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,131%, being 854% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	7,009
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,361
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	883
Other Liabilities	0
Other Net Income	7,724
Property and Equipment	0.57
Research and Development	17,126
Revenues	0
Selling, General and Administrative Expense	4,027

Output Variable	Value in 1000 USD
Assets	7,009
Liabilities	2,361
Expenses	22,036
Stockholders Equity	4,648
Net Income	-14,312
Comprehensive Net Income	-14,312
Economic Capital Ratio	-1,131%

